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The relevance of chiral fluorohydrins has been highlighted 
with the recent development of novel methodologies based on, 
e.g. the use of transition metal catalysis applied to nucleophilic or 
electrophilic fluorination,
1
 through the aperture of epoxides
2
 or 
the reduction of the corresponding ketones.
3
 These compounds 
are very interesting precursors for agrochemicals and 
pharmaceuticals,
4
 and they also present a remarkable role as 
liquid crystals,
5
 and as radiotracers when they are 
18
F-labeled for 
positron emission tomography (PET).
6
 
In particular, fluoromisonidazole (FMISO or F-MISO), 1-(2-
nitroimidazol-1-yl)-3-fluoropropan-2-ol (1, Scheme 1), is a 
derivative of the nitroimidazole group of compounds which have 
widely been investigated as hypoxic cell sensitizers. 
18
F-Labeled 
derivative of F-MISO has extensively been used to image 
hypoxic tissues in vivo with PET technology and also to predict 
cancer recurrence in living cells.
7
 
Since this compound presents a chiral center at position 2, it is 
administrated in its racemic form although it is well-known that 
the biological activity of a racemate can largely differ from each 
enantiomer.
8
 Among the different methodologies described to 
obtain this derivative, it can be highlighted the synthesis through 
fluoride displacement of a primary tosylated alcohol, and 
subsequent deprotection of the tetrahydropyranyl protecting 
group from the secondary alcohol under acidic conditions 
(Scheme 1A).
9
 Very recently it has been proposed the first 
asymmetric synthesis of (S)-1 via enantioselective aperture of an 
epoxide precursor with 1,1,1,3,3,3-hexafluoroisopropanol 
(HFIP), 5-diazabicyclo[4.3.0]non-5-ene (DBN), benzoyl fluoride, 
and a linked (salen)Co catalyst to achieve the kinetic resolution 




Scheme 1. Previous synthesis of: A) racemic labeled, and B) 
enantioenriched unlabeled F-MISO. 
 
Due to the short half-life of 
18
F-labeled F-MISO, it would be 
highly desirable to find a methodology that could easily afford 
both stable unlabeled F-MISO antipodes so the different 
biological properties of each enantiomer could be more easily 
assessed. To achieve this goal, here we propose the synthesis of a 
fluorinated ketone precursor (5, Scheme 2) that could be 
selectively reduced employing stereocomplementary alcohol 
dehydrogenases (ADHs),
11
 enzymes able to achieve the selective 
reduction of carbonyl compounds or the oxidation of alcohol 
derivatives under mild hydrogen transfer reaction conditions in 
aqueous medium. Starting from this prochiral ketone, this 
methodology could afford the final enantiopure fluorohydrin in a 
theoretical yield of 100%. 
Therefore, in order to obtain ketone 5, the straightforward 
synthesis shown in Scheme 2 was envisaged. Starting from 
commercially available 2-nitroimidazole 2 and 1,3-
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dichloroacetone 3, the chlorinated ketone 4 could be 
synthesized through nucleophilic substitution, which would 
afford desired ketone 5 using a fluoride source. 
 
Scheme 2. Proposed retrosynthesis to obtain fluorinated 
ketone 5. 
 
In a first set of experiments, different ratios of compounds 2 
and 3 were treated with several solvents and bases under various 
temperatures to synthesize ketone 4, although it was noticed that 
in many cases disubstituted derivative 6 was also obtained as a 
by-product (Table 1). Thus, using an equimolar ratio between 
compounds 2 and 3 to minimize the formation of 6, 
dichloromethane (entry 1), acetone (entries 2 and 3), and 
acetonitrile (entries 4 and 5) were employed at different 
temperatures in the presence of sodium carbonate as the base, 
observing that while for the first solvent no reaction occurred, 
probably due to the low solubility of the base, better results were 
achieved with the other two solvents, although undesired ketone 
6 (14-30%) was obtained as a by-product. Since the use of 
acetonitrile allows higher reaction temperatures, we further 
studied more conditions with this organic solvent. When the 
process was performed under reflux (entries 6 and 7), the 
employment of 3 equivalents of the base helped to achieve a 
higher conversion of ketone 4, obtaining 57% of conversion after 
2 h. Potassium carbonate was also used (entry 8) under these 
conditions, affording 64% of conversion of ketone 4 after 2 h of 
reaction. In another set of experiments, triethylamine was studied 
as the base to get access to the desired derivative (entries 9 to 
14). While at room temperature a maximum of 57% of 
conversion at 24 h was achieved using a 1:1 ratio between 2 and 
3 (entry 11), the employment of lower temperatures and a higher 
amount of 1,3-dichloroacetone afforded very low yields of 
undesired ketone 6, although conversions of chlorinated 
derivative 4 were also low (up to 31%, entries 13 and 14). 
To achieve a faster and more efficient synthesis, the reaction 
was carried out under microwave conditions,
12
 studying again 
different parameters in order to optimize this transformation 
(Table 2). Thus, when this process was performed in the absence 
of a base (entries 1 to 3), even at temperatures of 175ºC the 
conversion of ketone 4 was extremely low. Therefore, several 
basic compounds were added into the reaction medium to obtain 
higher conversions with good selectivities. While the proportion 
between 2 and 3 was kept 1:3 to minimize the formation of 6, a 
substoichiometric amount of the base (0.5 equivalents) was 
selected to compare their efficiency as catalysts, and among 
them, triethylamine (entry 7), 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU, entry 11), and potassium carbonate (entry 14) afforded the 
best results (43-75%) after 10 min at 80ºC, forming disubstituted 
ketone 6 in very low quantities (<10%). A lower amount of the 
base (entry 6) or the addition of 1,3-dichloroacetone 3 in portions 
(entry 13) did not improve the previous results, although leaving 
the reaction for a longer time (entry 12), slightly enhanced the 
formation of derivative 4. Then, the transformations were carried 
out with these three bases in stoichiometric quantity during 30 
min (entries 15 to 17), and it was clearly observed that K2CO3 
appeared as the best one affording a high conversion of the 
desired compound (86%) avoiding the formation of ketone 6. 
Gladly, under these conditions and just after 2 min of reaction, 
the same results were observed (entry 19), and the employment 
of higher temperatures (entry 20), did not improve the conversion 
obtained, so conditions shown in entry 19 were selected as the 
most appropriate to synthesize derivative 4. 
 
 
Table 1. Synthesis of α-chloro ketone 4 by reaction of nitroimidazole 2 and 1,3-dichloroacetone 3 in the presence of different 
bases. 
 
Entry Ratio 2:3 Conditions t (h) 2 (%)a 4 (%)a 6 (%)a 
1 1:1 CH2Cl2, 41ºC, inert atmosphere, Na2CO3 (1 equiv.) 24 >97 <3 <3 
2 1:1 acetone, rt, Na2CO3 (0.5 equiv.) 48 28 51 21 
3 1:1 acetone, 56ºC, Na2CO3 (0.5 equiv.) 24 15 57 28 
4 1:1 CH3CN, rt, Na2CO3 (0.5 equiv.) 48 40 46 14 
5 1:1 CH3CN, 56˚C, Na2CO3 (0.5 equiv.) 24 12 58 30 
6 1:1 CH3CN, 82ºC, Na2CO3 (0.5 equiv.) 2 <3 43 57 
7 1:1 CH3CN, 82ºC, Na2CO3 (3 equiv.) 2 <3 57 40 
8 1:1 CH3CN, 82ºC, K2CO3 (3 equiv.) 2 26 64 10 
9 1:1 CH3CN, rt, Et3N (1 equiv.) 1 67 28 5 
10 1:1 CH3CN, rt, Et3N (1 equiv.) 2 57 36 7 
11 1:1 CH3CN, rt, Et3N (1 equiv.) 24 22 57 21 
12 1:1 CH3CN, rt, Et3N (1 equiv.) 48 22 56 22 
13 1:2 CH3CN, 0˚C, Et3N (1 equiv.) 1 80 20 <3 
14 1:2 CH3CN, 0˚C, Et3N (1 equiv.) 2 65 31 4 
a Measured by 1H-NMR. 
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Table 2. Synthesis of α-chloro ketone 4 by reaction of nitroimidazole 2 and 1,3-dichloroacetone 3 (molar proportion 1:3) under 
microwave conditions. 
 
Entry Conditions MW setup t (min) 2 (%)a 4 (%)a 6 (%)a 
1 CH3CN 150˚C, 300 W, 250 psi 10 >97 <3 <3 
2 CH3CN 175˚C, 300 W, 250 psi 30 96 4 <3 
3 CH3CN/DMSO (4:1) 150˚C, 200 W, 250 psi 10 >97 <3 <3 
4 CH3CN, NH3 (0.5 equiv.) 80˚C, 200 W, 250 psi 10 92 8 <3 
5 CH3CN, Py (0.5 equiv.) 80˚C, 200 W, 250 psi 10 >97 <3 <3 
6 CH3CN, Et3N (0.2 equiv.) 80˚C, 200 W, 250 psi 10 79 20 <3 
7 CH3CN, Et3N (0.5 equiv.) 80˚C, 200 W, 250 psi 10 54 43 3 
8 CH3CN, DMAP (0.5 equiv.) 80˚C, 200 W, 250 psi 10 82 16 <3 
9 CH3CN, DABCO (0.5 equiv.) 80˚C, 200 W, 250 psi 10 82 13 5 
10 CH3CN, piperidine (0.5 equiv.) 80˚C, 200 W, 250 psi 10 79 20 <3 
11 CH3CN, DBU (0.5 equiv.) 80˚C, 200 W, 250 psi 10 48 48 4 
12 CH3CN, DBU (0.5 equiv.) 80˚C, 200 W, 250 psi 30 43 53 4 
13b CH3CN, DBU (0.5 equiv.) 80˚C, 200 W, 250 psi 10+10+10 43 43 14 
14 CH3CN, K2CO3 (0.5 equiv.) 80˚C, 200 W, 250 psi 10 15 75 10 
15 CH3CN, Et3N (1 equiv.) 80˚C, 200 W, 250 psi 30 46 48 6 
16 CH3CN, DBU (1 equiv.) 80˚C, 200 W, 250 psi 30 34 62 4 
17 CH3CN, K2CO3 (1 equiv.) 80˚C, 200 W, 250 psi 30 14 86 <3 
18 CH3CN, K2CO3 (1 equiv.) 80˚C, 200 W, 250 psi 10 17 83 <3 
19 CH3CN, K2CO3 (1 equiv.) 80˚C, 200 W, 250 psi 2 14 86 <3 
20 CH3CN, K2CO3 (1 equiv.) 120˚C, 200 W, 250 psi 2 16 84 <3 
a Measured by 1H-NMR. b 1,3-Dichloroacetone was added in three portions every 10 min of microwave reaction. 
 
This transformation was achieved at 2 mmol scale obtaining, 
after 2 min of MW reaction and purification, compound 4 in 78% 
isolated yield. As the next step, fluorination of this ketone to 
obtain 5 (Scheme 2), was tried under several conditions. Hence, 
the use of KF and ZnF2 in CH3CN at 120˚C for 24 h;
13
 PhCOF, 
HFIP and DBU in TBME at 50˚C for 24 h;
10
 or CsF in CH3CN 
under reflux for 24 h in the presence or in the absence of 18-
crown-6, did not afford any conversion recovering the starting 
chlorinated ketone. Due to this, the corresponding chlorohydrin 7 
was synthesized by reduction of 4 using NaBH4 in MeOH at 0ºC 
in 97% yield, and then the nucleophilic fluorination over this 
compound was also tried. In this case it was observed the 
formation of a new derivative when employing KF and ZnF2 or 
CsF with 18-crown-6 in CH3CN, although unfortunately it was 
not the desired racemic F-MISO but epoxide 8 (Scheme 3). 
 
Scheme 3. Fluorination conditions over chlorohydrin 7 
afforded epoxide 8. 
 
Due to the fact that this strategy seemed to be not appropriate 
to obtain the fluorinated ketone 5, precursor of enantioenriched 
F-MISO antipodes, the synthetic route was modified. Since 1-
chloro-3-fluoropropan-2-ol (9) is commercially available, it was 
envisaged the oxidation of this derivative into 1-chloro-3-
fluoroacetone (10), which under the previous optimized MW 
reaction conditions could directly afford the final derivative 5. 
Due to the high difficulty to oxidize halohydrins,
14
 it was 
envisioned the employment of a potent oxidant such as Jones’ 
reagent. Thus, following a typical procedure,
15
 using a mixture of 
acetone/water (40:1 v v
-1
) at 0ºC afforded, by TLC, the desired 
compound, but when the solvent was evaporated under vacuum 
to obtain 10, the high volatility of this ketone avoided its 
adequate isolation. In order to circumvent this fact, the use of 
microwave conditions in the absence of an organic solvent 
employing just alcohol 9 with the Jones’ reagent under different 
setups was done (see Supplementary Data). Hence, a temperature 
of 80ºC was too high since several by-products were observed in 
the reaction crude, therefore 60ºC was fixed as the most 
adequate. Maintaining a pressure of 250 psi, several powers 
(from 10 to 200 W) and reaction times (from 5 to 15 min) were 
studied, but in some cases the formation of by-products was still 
detected or incomplete transformations were achieved, so finally 
10 W during 15 min were chosen as the most appropriate 
Tetrahedron 4 
conditions to obtain ketone 10 after extraction with diethyl 
ether in excellent yield (>95%). 
 
Scheme 4. One-pot two-step synthesis of ketone 5 under MW 
conditions. 
 
The subsequent nucleophilic substitution of ketone 10 with 2-
nitroimidazole 2 was carried out following the reaction 
conditions shown in entry 19 from Table 2 obtaining, by NMR, a 
conversion of 63% of fluorinated ketone 5. A longer time (30 
min) and a higher number of K2CO3 equivalents (7), improved 
the conversion until 70%. Due to the fact that both processes 
followed similar MW conditions and since, at first, no reagent 
incompatibilities were envisaged, the one-pot two-step procedure 
at 1 mmol scale was performed avoiding the isolation of volatile 
ketone 10, thus synthesizing derivative 5 in 60% of isolated yield 
(Scheme 4). As can be noted, the reaction times were longer to 
achieve similar conversions than at smaller scale. 
Having in hand α-fluoro ketone 5, precursor of both F-MISO 
enantiomers, and α-chloro ketone analogue 9, we decided to use 
different alcohol dehydrogenases with opposite stereopreference 
to synthesize both alcohol antipodes. Thus, among the different 
ADHs we have in our laboratory, alcohol dehydrogenase from 
Rhodococcus ruber ADH-A overexpressed in E. coli (E. 
coli/ADH-A),
16
 and commercially available ADH from 
Lactobacillus brevis (LBADH)
17
 were used. The transformations 
were performed in Tris.HCl buffer 50 mM pH 7.5 1 mM 
NAD(P)H using 2-propanol (5% v v
-1
) to recycle the 
nicotinamide cofactor in a ‘coupled-substrate’ approach
11
 and to 
solubilize the hydrophobic substrate in the reaction medium. 
Thus, ketone 5 was reduced at 30 mM concentration by E. 
coli/ADH-A and LBADH (Scheme 5) affording, respectively, 
enantiopure (R)- and (S)-1 in >99% and 92% of conversion after 
24 h. The bioreduction was especially fast with ADH-A, 
achieving 86% of conversion after 1 h (see Supplementary Data). 
On the other hand, chlorinated substrate 4 was reduced by both 
biocatalysts giving rise to enantiopure (R)- and (S)-7 with 
quantitative conversion. These transformations were performed at 
higher substrate concentration (100 mM) allowing the synthesis 
of both antipodes of F-MISO in high to excellent conversions 
(75% for LBADH and >99% for E. coli/ADH-A) while the 
chlorinated analogue showed also high conversions (75% for 
LBADH and 86% for E. coli/ADH-A) after 24 h. 
 
Scheme 5. ADH-catalyzed synthesis of both enantiopure 
antipodes of alcohols 1 and 7. 
 
Herein we have described an efficient protocol to synthesize 
both enantiopure fluoromisonidazole antipodes via one-pot two-
step microwave protocol synthesis of ketone 5 plus bioreduction 
catalyzed by two stereocomplementary ADHs under the 
‘coupled-substrate’ approach using 2-propanol as the hydrogen 
donor. Moreover, after extensive optimization, the chlorinated 
analogue 4 could also be synthesized through MW reaction and 
was an excellent substrate for ADH-A and LBADH, affording 
both chlorohydrin enantiomers in enantiomerically pure form. 
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